LEO Pharma has applied to the EMA to expand the label for Anzupgo (delgocitinib) cream to include adolescents.

China’s focus on first or best-in-class oncology drugs and innovative R&D will help it to secure further licensing deals in ...

US-based private investment company SK Capital Partners’ affiliate is to invest in Swixx BioPharma to support its growth and ...

Akeega’s is now FDA indicated for mCSPC and mCRPC, widening the drug’s future market potential across the prostate cancer ...

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.